Beleaguered Rennova Health Inc (NASDAQ:RNVA) Can’t Hold Morning Gains

Rennova Health Inc (NASDAQ:RNVA)

Rennova Health Inc (NASDAQ:RNVA) has lost close to 98% of its value over the past year. That is a worrisome figure made worse by the fact that the S&P Healthcare ETF, XLV, is up almost 20% over the same period. However today RNVA stock attempted a rebound on heavy volumes.

Shares of Rennova Health Inc (NASDAQ:RNVA) closed Monday at $1.43, then opened today at $1.45 before rocketing in morning trading to a high of $1.78. As of this writing (12:50 AM EST), RNVA stock is trading below yesterday’s close. Volumes have been curiously heavy for a stock that has a 30-day, daily average volume of just 82,620. So far, over 1.55 million shares have traded.

Rennova Health Inc (NASDAQ:RNVA)

Rennova Health Inc (NASDAQ:RNVA) is based in West Palm Beach, FL. The company provides diagnostics and software solutions to the healthcare industry such as diagnostic laboratory testing and analytics for precision medicine, specialized and streamlined electronic health records. Rennova Health also supplies integrated medical billing solutions. The company also provides loans to healthcare providers that are collateralized by their accounts receivable.

RNVA Stock Performance

When adjusting for dilution, RNVA shares have a 52-week high of $103.50 – that is not a misprint. The 52-week low is $1.38 – just pennies above current trading levels. The Relative Strength Index stands at 15.25. Many traders believe that a figure below 20 represents a definite “oversold” condition which may explain the mornings heavy buying. However, traders were quick to take profit.

In 2015 Rennova Health Inc (NASDAQ:RNVA) had sales of $18.4 million but that number dropped to just $5.2 million for 2016. Unfortunately, the number of outstanding shares more than doubled in those years as Rennova Health raised funds by issuing more shares thereby diluting shareholder value. Only one firm rates RNVA shares and gives them a “Hold”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RNVA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Aethlon Medical, Inc. (NASDAQ:AEMD) Partners with iBio Inc.

Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon Medical, Inc. (NASDAQ:AEMD) shares fell 3.88% after announcing the formation of a large scale production collaboration agreement with iBio, Inc. (NYSE AMERICAN: IBIO). The primary goal of the collaboration is to advance the large-scale production of Galanthus nivalis agglutinin (GNA), a plant-derived lectin in Aethlon’s Hemopurifier.

Aethlon-iBio Partnership

According to iBio President, Barry Holtz, a collaboration of the two companies is an ideal combination for the delivery of new therapeutic approach for pandemic diseases and biothreats. Researchers from the two companies have already completed a feasibility study that sought to produce highly active recombinant GNA with iBio’s plant technology.

Jim Joyce, Chairman and CEO of Aethlon stated, “The production of recombinant GNA in iBio’s large-scale manufacturing facilities establishes a pathway for us to access a consistent, high-quality supply that can support our long-term clinical and commercialization objectives,”

Aethlon Hemopurifier is a first-class therapeutic device that the U.S. Food and Drugs Administration (FDA) has awarded Expedited Access Pathway for the treatment of life-threatening viruses. The biotechnology company has already validated the device’s ability to capture a broad spectrum of pandemic influenza viruses as well as mosquito-borne viruses and deadly hemorrhagic viruses.

Aethlon Medical, Inc. (NASDAQ:AEMD) is currently investigating the potential use of the Hemopurifier to reduce the presence of tumor-derived exosomes which suppresses immunity and leads to a spread of metastasis in cancer patients.

AEMD Stock Performance

Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon’s stock underperformance continued in Monday’s trading session as the stock came under pressure from sellers. The stock is currently trading at multi-year lows after losing more than 70% in market value since the start of the year. The stock dropping below the $1 a share is already arousing concerns about the stock’s continued listing status in the market.

Last week Aethlon Medical, Inc. (NASDAQ:AEMD) issued a statement indicating that the NASDAQ had formally notified it that it complied with all the applicable required listing requirements. While one of the requirements is a $2.5 million stockholder equity position, the share price is also required to be above $1 a share for continued listing

Aethlon Medical, Inc. (NASDAQ:AEMD) is in need of new catalysts if it is to gain favor among investors and bounce back from current trading levels.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AEMD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) Drops After Pricing

Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE)

Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) shares fell 13.36% after the development stage biopharmaceutical company announced it had entered into a securities purchase agreement with certain investors. Pursuant to the agreement, the company has agreed to sell approximately $6.75 million worth of shares at a price of $0.875 a share.

AMPE Stock Investor Reaction

The offering will to close on or about October 18, 2017. Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) plans to use the net proceeds for working capital and general corporate purposes. Proceeds will also to be used for to fund the Ampion clinical trial.

The share offering appears to have spooked investors. The stock had been on an impressive run for the last month. Over the past month, AMPE is up by more than 100% as it continues its recovery from multi-year lows of $0.42 a share. However, the stock has underperformed the overall industry and is down by more than 10% compared to its January levels.

Ampion Clinical trials

Separately, Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) has completed enrollment and dosing of patients as part of a 12-week pivotal study of Ampion on patients with severe osteoarthritis of the knee (OAK). The primary endpoint of the study follows the Osteoarthritis Research Society International guidance.

“Announcing the close of enrollment so quickly speaks to the unmet medical need. We have found Ampion™ to be both safe and effective in the clinical development of over 1900 patients, many of whom have no other alternative treatment options,” said CEO Michael Macaluso.

Ampion is currently in late-stage study for the treatment of signs and symptoms of OAK. A recent randomized placebo-controlled trial focused on a subset of patients with severe OAK. The study examined the safety and efficacy of an intra-articular injection of Ampion compared to Saline.

Trial results indicate that a single injection of Ampion was well tolerated across all trials with patients showing significant response compared to saline.

Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) remains confident that the U.S. Food and Drug Administration (FDA) will approve Ampion as a reference product. If achieved, that will grant it 12 years of exclusivity. Ampio already has patent coverage in major jurisdictions of the likes of Europe, Brazil, Australia and Canada.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AMPE and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Directionless Akers Biosciences Inc (NASDAQ:AKER)

Akers Biosciences Inc (NASDAQ:AKER)

Akers Biosciences Inc (NASDAQ:AKER) stock is unchanged in the after-hours market after dropping over 15% today on heavy volume. No news was released that might account for the price drop. However AKER shares had been trending down or sideways since early April. The biotech firm hit its 52-week low of $0.70 in early October before jumping above $1.75 last week. Two days of losses followed that large move upwards.

Akers Biosciences Inc (NASDAQ:AKER)

About Akers Biosciences

West Deptford, NJ-based Akers Biosciences Inc (NASDAQ:AKER) was founded in 1989. The company develops in vitro diagnostic technologies that allow clinicians, and in some cases consumers, more quickly obtain health information. Their proprietary tests and sample preparation devices provide the same level of accuracy as traditional laboratory testing methods, but at a fraction of the cost and turn-around time. The company offers a alcohol breath detector, a breath ketone device for weight loss, and a device to measure oxidative stress among others.

In March Akers shares jumped when First Check Diagnostics, LLC placed an order with Akers Biosciences Inc (NASDAQ:AKER) for its cholesterol self-test. First Check Diagnostics LLC owns the First Check brand. Its products are distributed through such well-known stores such as CVS, Rite Aid, Target, and Kmart.

AKER Stock Review

Although AKER shares have a target price of $4, the shares have spent a considerable amount of time below $1 which is a threshold compliance level for the NASDAQ Market. A prolonged absence from a pricing above $1 may force the NASDAQ to issue a warning notice, and if unaddressed, a potential delisting. Akers Biosciences Inc (NASDAQ:AKER) stock has a 52-week high of $3.60 which was reached in late 2017. The 52-week low of $0.70 was hit in late September.

Sales and earnings have been inconsistent over the years. The company posted sales of just $1.6 million in 2012 and in 2014 hit a high of $4.4 million. However last year Akers posted a sales figure of only $3 million. Similarly, per share losses have been a regular event but there has been no trend that could provide investors with more confidence on the stock’s direction. In 2012, there was a per share loss of (-$2.24). That was followed by two years of lower losses but then in 2015 the loss expanded to (-$1.81), but then shrank to (-$0.61) for 2016. Unfortunately, the trend in the number of outstanding shares has been clear. In 2012 there were 1.14 million outstanding shares. That number has increased, and diluted shareholder value, every year. By 2016 the number of outstanding shares was posted at 5.43 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AKER and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

FDA Approval Rockets Transenterix Inc (NYSEAMERICAN:TRXC)

Transenterix Inc (NYSEAMERICAN:TRXC)

Medical device company Transenterix Inc (NYSEAMERICAN:TRXC) stock is up around 60% on very heavy volumes after the company won FDA approval for their Senhance Surgical Robotic System. After Friday’s close, the company released the news that the U.S. Food and Drug Administration (FDA) had received FDA 510(k) clearance which makes their device the first new market entrant into the field of abdominal surgical robotics since 2000.

Transentrix Business

TransEnterix, located in Morrissville, NC, is a medical device company that develops and markets robotics to improve minimally invasive surgery by addressing the clinical and economic challenges related to existing laparoscopic and robotic options. It distributes its products globally.

The Senhance Surgical Robotic System is Transentrix’s lead product. It is a multi-port robotic surgery system, which allows up to four arms to control robotic instruments as well as a camera. Transenterix Inc (NYSEAMERICAN:TRXC) also develops the SurgiBot System. It is a single-port, robotically enhanced laparoscopic surgical platform. In addition, the company develops and manufactures flexible and rigid laparoscopic surgical instruments that are used in abdominal surgery.

TRXC Stock Performance

Before today’s action, TRXC stock had attempted, and failed, in recent weeks to break through the $1.50 price level. Last Friday the stock closed at $1.46. This morning, after traders digested the news released last Friday, shares opened at $2.78 and reached $2.85. As of this writing (11:50 AM EST) TRXC shares have dropped down to $2.35. However that price is above TRXC’s 52-week high of $2.19. The volume is very heavy – over 80 times the posted average.

Prior to this morning’s run, shares of Transenterix Inc (NYSEAMERICAN:TRXC) were down 27% for the year but up almost 80% for the quarter. That upward swing is reflected in the Relative Strength Index which stood at 85 before this morning’s open. A figure above 70 normally triggers an “overbought” condition for most traders. That may explain the shares coming off their $2.85 daily high so quickly.

Transentrix Earnings and Sales

Transenterix Inc (NYSEAMERICAN:TRXC) has posted per share losses every year since 2012. For 2016 the per share loss was (-$1.07) which followed a loss of (-$0.59) in 2015. The medical device company posted no sales for 2015 but for 2016 the figure was $1.5 million. One point of serious concern for investors has to be share dilution. In 2012 there were 1.08 million shares outstanding. That figure has grown each year and for 2016 stood at 112.19 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TXRC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

CASI Pharmaceuticals Inc. (NASDAQ:CASI) Falls After Pricing

CASI Pharmaceuticals Inc. (NASDAQ:CASI)

CASI Pharmaceuticals Inc. (NASDAQ:CASI) shares fell 25.3% after the biopharmaceutical company announced the signing of definitive agreements with certain institutional and accredited investors. Pursuant to the agreement, the company will sell an aggregate of 7.95 million shares of its common stock and warrants for the purchase of additional shares.

CASI Pharmaceuticals Inc. (NASDAQ:CASI)

Public Offering Reaction

Investors reacted to the news by sending the stock lower as the issuance of shares will result in further dilution of the stock. Last week’s sell-off is already threatening to reverse a bullish run that had pushed the stock to a 52-week high of $4.84 a share. Over the past few days, the stock has shed more than 40% in market value. However, it is still up by more than 100% for the year.

The biopharmaceutical company is expecting approximately $23.8 million from the registered direct offering. Net proceeds from the offering are to be used to support business development projects.

In addition, CASI Pharmaceuticals Inc. (NASDAQ:CASI) Chairman Dr. Wei-Wu He has echoed his support for China’s FDA push to accept data from clinical trials outside China. According to the executive, the move will accelerate approval of imported drugs.

“We believe this could potentially accelerate our pipeline of U.S. approved drugs that are currently under China FDA review, namely EVOMELA®, which has been granted priority review; and MARQIBO® and ZEVALIN®. We look forward to accelerating these medicines to the second largest pharmaceutical market, and will continue to add on to our pipeline,” said Mr. He.

CFDA Import Drug Accelerated Approval

China’s FDA has already granted a priority review for EVOMELA, for the treatment of multiple myeloma, which is classified as a rare disease in the country. The agency is also reviewing an application for approval of MARQIBO for the treatment of adult patients with Philadelphia chromosome negative lymphoblastic leukemia. A review of the drug is set to be complete in the next four to six weeks.

The CFDA is also reviewing, CASI Pharmaceuticals Inc. (NASDAQ:CASI) import drug clinical trial application (CTA) for ZEVALIN. The intravenous injection is indicated for the reduction of the number of B-cells in the blood and for the treatment of non-Hodgkin’s lymphoma (NHL).

“[..] it also is a positive signal from the CFDA to accelerate the import drug registration process for U.S. FDA approved drugs in order to address the significant unmet medical needs of the Chinese population in an accelerated time frame,” said CEO, Ken Ren.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CASI Symbol and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Tandem Diabetes Care Inc. (NASDAQ:TNDM) Falls

Tandem Diabetes Care Inc. (NASDAQ:TNDM)

Tandem Diabetes Care Inc. (NASDAQ:TNDM) felt the wrath of Wall Street after announcing the pricing of an underwritten offering of shares of its common stock. Shares of the company fell 36.11% to end up at multi-year lows of $2.99 a share.

Friday’s sell-off capped yet another poor run in the stock’s performance this year. Tandem Diabetes Care Inc. (NASDAQ:TNDM) is down by more than 80% for the year as it continues to trade in a strong downtrend. Concerns about the company’s financial health remains a point of concern among investors.

Tandem Diabetes Care Inc. (NASDAQ:TNDM)

The medical device company and manufacturer of the only touchscreen insulin pumps plans to raise additional capital through the issuance of 4.6 million shares of common stock priced at $3.50 a share. The company is also offering Series A warrants for the purchase of 4.6 million shares and Series B warrants for the purchase of 4.6 million shares.

Tandem Diabetes expects gross proceeds of $16.2 million from the public offering. The company intends to use net proceeds from the offering for working capital among other general corporate purposes.

Reverse Stock-Split

The pricing of the public offering comes just days after a special meeting of shareholders approved a reverse stock split of the company’s issued and outstanding shares of common stock. The approval paves way for Tandem Diabetes Care Inc. (NASDAQ:TNDM) to initiate a split ratio of not less than 1-fo-8 and not greater than 1-for-12.

Completion of the reverse stock split will result in shares of common stock remaining at 100 million shares.

“The implementation of this reverse stock split will provide us with flexibility in our capital structure to pursue financing alternatives in support of our business plan and to bring new innovations to people with diabetes,” said Kim Blickenstaff, President, and CEO of Tandem Diabetes Care.

Insulin Pump Approval

The pricing of the public offering follows FDA approval of the company’s fifth insulin pump in five years. The company is to begin commercial launch of t: slim X2 Insulin Pump, which is the first sensor-augmented insulin pump that lets users make treatment decisions without pricking their fingers.

The new insulin pump is also the only one in the market capable of conveniently displaying user’s insulin delivery activity and Dexcom G5 Mobile CGM data on a single device.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TNDM Symbol and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

The Story Behind the Volatility on Roka Bioscience Inc (NASDAQ:ROKA)

Roka Bioscience Inc (NASDAQ:ROKA)

Roka Bioscience Inc (NASDAQ:ROKA) continued to exhibit extraordinary volatility as the biotech firm stock closed Friday down over 12% on 4.5 million shares traded – well above the 30-day, daily average of under 700,000. Despite the drop, ROKA stock has gained 94% over the past month and over 140% over the past week.

Roka Bioscience Inc (NASDAQ:ROKA)

The action began last Tuesday when ROKA stock traded over 25 million shares – just over 166,000 shares had traded. Since mid-July, the stock had traded over 1 million shares exactly twice. The catalyst of last Tuesday’s increased volume and 155% price spike likely was the news that AJA Pharmaceuticals CEO Edward Painter had acquired a 6.89% stake in Roka Bioscience Inc (NASDAQ:ROKA). Painter ended up with a stock purchase totaling 340,000 shares using his personal funds. Reportedly his intention is to pursue an undisclosed business arrangement with his privately held biotech.

ROKA Stock Analysis

On Tuesday, the day the Painter purchase was disclosed, shares hit a high of $2.55 and closed at $1.90. Last Friday, shares tested the $2.55 Tuesday high but got to only $2.43. Accordingly, shares dropped back to $1.92 – just $0.02 above the Tuesday close. Traders claim that, barring more news, it is unlikely to test the Tuesday/Friday highs again until the company announces its earnings on November 17, after the market closes.

One investment firm analyst covers Roka Bioscience Inc (NASDAQ:ROKA) and gives the shares a “Buy” rating with a price target of $10. However, that rating should be viewed in some context. The analyst’s report is almost a year old and the stock has declined over 70% in the past year.

Reported sales for Roka Bioscience Inc (NASDAQ:ROKA) have been impressive. In 2012, the company reported a sales figure of $100,000. That figure has improved every year since and, in 2016, was an impressive $7.2 million. Regrettably, the increase in sales has not shown up in the biotech’s earnings. For 2016, the company reported a per share loss of (-$17.42). Between 2012 and 2015 per share losses ranged from ($13.15) to (-$29.30). Share dilution has also been a problem. In 2014 there were 1.4 million ROKA shares outstanding and by 2016 that number had expanded to 2.21 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ROKA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Why PhaseRx Inc (NASDAQ:PZRX) Had Increased Volatility Today

PhaseRx Inc (NASDAQ:PZRX)

PhaseRx Inc (NASDAQ:PZRX) stock is up over 15% in late-day trading after the biopharmaceutical company’s Board of Director’s approved a workforce reduction as part of a restructuring effort. PZRX shares hit a high of $1.89 earlier before sellers stepped in. Volumes have been heavy. PZRX shares are listed with a 30-day, daily volume figure of less than 65,000, but by 2:15PM almost 7 million shares have traded hands.

PZRX Stock Chart over the last two days:

PhaseRx Inc (NASDAQ:PZRX)
2 day Stock Chart

PhaseRx Recent Developments

Less than a month ago, PhaseRx Inc (NASDAQ:PZRX) was touting the granting of an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its candidate drug PRX-ASL. PRX-ASL is being developed as a potential treatment for argininosuccinate lyase deficiency (ALSD). ASLD is a rare liver disorder caused by an inherited single-gene deficiency that results in elevated ammonia in the blood and can lead to irreversible neurological impairment, coma, and death.

The FDA grants orphan drug designation to investigational drugs that are being developed for the treatment of rare diseases that affect fewer than 200,000 people in the U.S. The designation of “Orphan Drug” is used to help the drug developers, including assistance with clinical study design and drug development, and providing tax credits for certain clinical trial expenses, exemptions from certain FDA application fees, and seven years of market exclusivity upon regulatory product approval.

PhaseRx Cost Cutting Ahead

The decision to restructure PhaseRx Inc (NASDAQ:PZRX) is aimed to reduce short term operating costs and delay the development of its lead product candidate PRX-OTC. The restructuring will include a 50% workforce reduction. The moves are being made to extend the life of the company as it seeks further alternatives that could include a merger or sale. As of June 30, 2017, PhaseRx had cash and equivalents of $8.4 million and a total of 20 employees.

PZRX Stock

PZRX stock has been in a downward trend since February. Its 52-week high was $3.30 and its low, achieved in late September, was $0.54. Since then the stock has experienced a bit of a rebound. However, investors in PhaseRx Inc (NASDAQ:PZRX) are apparently not keen to fully buy into the restructuring as PZRX shares are trading below today’s opening levels.

 

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PZRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Zosano Pharma Corp (NASDAQ:ZSAN) Spikes On Migraine Data

Zosano Pharma Corp (NASDAQ:ZSAN) Spikes On Migraine Data

Zosano Pharma Corp (NASDAQ:ZSAN) traded higher after announcing the publication of positive pivotal data for its proprietary Adhesive Dermally-Applied Microarray technology. The stock was up by 5.6% in Thursday’s trading session, to end the day at $1.13 a share.

ZSAN Stock Performance

Shares of Zosano Pharma Corp (NASDAQ:ZSAN) are currently trading in a downtrend, after dropping from $3.50 a share in February. While the stock is slightly up for the year, it has underperformed the overall industry. Data compiled by Zacks Investment Research indicates that the stock is rated as a ‘buy,’ by one analyst firm and as a ‘hold’ by another.

Zosano Pharma Corp (NASDAQ:ZSAN)

Zosano Pharma Corp (NASDAQ:ZSAN) is a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its ADAM technology. The investigational technology platform is designed to offer rapid drug absorption into the bloodstream resulting in improved pharmacokinetic profile compared to other dosage forms.

A publication by Cephalalgia contains positive results from Zosano Pharma Corp (NASDAQ:ZSAN)’s Zotrip Pivotal study. The multicenter, double-blind randomized trial analyzed the safety and efficacy of ADAM Zolmitriptan for the treatment of acute migraine.

“We are pleased to have the results of ZOTRIP, our pivotal study, published in Cephalalgia. The recognition of the results from ZOTRIP in such a well-known journal will continue to raise awareness of M207, and its ability to address an unmet need for patients struggling to find rapid and durable pain relief for migraine episodes,” said CEO John P. Walker.

Board Appointment

In addition to the publication, Zosano Pharma Corp (NASDAQ:ZSAN) has confirmed the appointment of Mr. Kenneth R. Greathouse to the board of directors. His experience in the field of neurology will be a key asset in bringing M207 to market.

He joins the company with over 40 years of experience in sales marketing and business development. Greathouse is also a co-founder of various pharmaceutical companies, including Manchester Pharmaceuticals.

“I look forward to working with the management team and Board as our lead program progresses towards an NDA filing and, if approved, towards commercialization,” said Mr. Greathouse.

Zosano Patent Application

Separately, Zosano Pharma Corp (NASDAQ:ZSAN) says it is in active discussions with the U.S Patent and Trademark Office (USPTO), regarding a patent application covering M207. The patent application details a method of rapidly achieving therapeutic concentrations of triptans for the treatment of migraines. If issued, the patent would extend coverage of the current patent from 2027 to 2037.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ZSAN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.